TON Web Exclusives

Five-year analysis of the phase 3 ALTTO trial showed no decided benefit to dual HER2 blockade over single-agent HER2-targeted therapy for the treatment of HER2-positive early-stage breast cancer. However, an indication for dual HER2 blockade use in HER2-positive, estrogen receptor–negative tumors is a possibility.
A modest reduction in the risk for invasive breast cancer was achieved by adding a second HER2-targeted agent to the treatment regimen for women with early-stage HER2+ breast cancer. The results suggest that the strategy may be appropriate in women at highest risk for recurrence.
Single-agent pembrolizumab produced durable responses in women with metastatic triple-negative breast cancer who have received prior chemotherapy for metastatic disease.
A 9-week course of trastuzumab as adjuvant therapy in women with hormone receptor–positive, early-stage breast cancer can maintain efficacy and reduce toxicity compared with the standard 1-year course of trastuzumab.
Two additional trastuzumab biosimilar agents demonstrate therapeutic equivalence to trastuzumab in women with HER2-positive breast cancer.
The global phase 3 MONARCH 2 trial showed a significant advantage to adding the CDK4/6 inhibitor abemaciclib to fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer.
Pembrolizumab improves response rates in the phase 2 I-SPY 2 trial of women with various subtypes of high-risk breast cancer.
For the first time, a PARP inhibitor used as monotherapy has proved superior to standard chemotherapy in the treatment of women with metastatic breast cancer with a germline BRCA mutation.
Palbociclib may reverse acquired resistance to endocrine therapy in women with hormone receptor‒positive, HER2-negative breast cancer.
An updated analysis of PALOMA-1 shows no significant survival advantage when palbociclib is added to letrozole in women with estrogen receptor–positive breast cancer.
Page 4 of 6
Results 31 - 40 of 55